228 related articles for article (PubMed ID: 9469303)
41. Secondary chondrosarcoma arising from osteochondroma: outcomes and prognostic factors.
Tsuda Y; Gregory JJ; Fujiwara T; Abudu S
Bone Joint J; 2019 Oct; 101-B(10):1313-1320. PubMed ID: 31564158
[TBL] [Abstract][Full Text] [Related]
42. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
[TBL] [Abstract][Full Text] [Related]
43. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
44. Gefitinib causes growth arrest and inhibition of metastasis in human chondrosarcoma cells.
Song J; Zhu J; Zhao Q; Tian B
J BUON; 2015; 20(3):894-901. PubMed ID: 26214645
[TBL] [Abstract][Full Text] [Related]
45. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas.
Kawashima A; Okada Y; Nakanishi I; Ueda Y; Iwata K; Roessner A
Gen Diagn Pathol; 1997 Feb; 142(3-4):129-37. PubMed ID: 9065576
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
47. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
48. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
49. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion.
Yuan J; Dutton CM; Scully SP
J Orthop Res; 2005 Nov; 23(6):1467-74. PubMed ID: 15927440
[TBL] [Abstract][Full Text] [Related]
50. Clinical outcome of central conventional chondrosarcoma.
Angelini A; Guerra G; Mavrogenis AF; Pala E; Picci P; Ruggieri P
J Surg Oncol; 2012 Dec; 106(8):929-37. PubMed ID: 22649023
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
52. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
53. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.
He L; Yang Z; Zhou J; Wang W
Clin Transl Oncol; 2015 Jun; 17(6):438-45. PubMed ID: 25387569
[TBL] [Abstract][Full Text] [Related]
54. Cysteine proteinases in chondrosarcomas.
Söderström M; Ekfors T; Böhling T; Aho A; Aro HT; Vuorio E
Matrix Biol; 2001 Jan; 19(8):717-25. PubMed ID: 11223331
[TBL] [Abstract][Full Text] [Related]
55. Metastatic Potential of Grade I Chondrosarcoma of Bone: Results of a Multi-institutional Study.
Andreou D; Gilg MM; Gosheger G; Werner M; Hardes J; Pink D; Leithner A; Tunn PU; Streitbürger A
Ann Surg Oncol; 2016 Jan; 23(1):120-5. PubMed ID: 26350369
[TBL] [Abstract][Full Text] [Related]
56. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs.
Kossakowska AE; Urbanski SJ; Huchcroft SA; Edwards DR
Oncol Res; 1992; 4(6):233-40. PubMed ID: 1421616
[TBL] [Abstract][Full Text] [Related]
57. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
58. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.
Uría JA; Balbín M; López JM; Alvarez J; Vizoso F; Takigawa M; López-Otín C
Am J Pathol; 1998 Jul; 153(1):91-101. PubMed ID: 9665469
[TBL] [Abstract][Full Text] [Related]
59. Distinct expression of gelatinase A [matrix metalloproteinase (MMP)-2], collagenase-3 (MMP-13), membrane type MMP 1 (MMP-14), and tissue inhibitor of MMPs type 1 mediated by physiological signals during formation and regression of the rat corpus luteum.
Liu K; Olofsson JI; Wahlberg P; Ny T
Endocrinology; 1999 Nov; 140(11):5330-8. PubMed ID: 10537164
[TBL] [Abstract][Full Text] [Related]
60. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
